Leerink Partners Boosts Natera (NASDAQ:NTRA) Price Target to $150.00

Natera (NASDAQ:NTRA) had its target price raised by equities researchers at Leerink Partners from $140.00 to $150.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Leerink Partners’ price objective would indicate a potential upside of 22.55% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. BTIG Research boosted their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. Robert W. Baird boosted their price target on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, UBS Group lowered their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Natera Trading Up 0.0 %

Shares of NTRA stock opened at $122.40 on Thursday. Natera has a 1 year low of $36.90 and a 1 year high of $133.54. The firm’s fifty day simple moving average is $123.30 and its 200 day simple moving average is $110.36. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the previous year, the firm posted ($0.97) earnings per share. Natera’s revenue was up 58.1% compared to the same quarter last year. Analysts expect that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the sale, the chief financial officer now owns 77,418 shares in the company, valued at approximately $8,314,693.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Michael Burkes Brophy sold 499 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the transaction, the chief financial officer now owns 77,418 shares in the company, valued at $8,314,693.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 549 shares of the company’s stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $57,732.84. Following the transaction, the insider now owns 113,637 shares in the company, valued at approximately $11,950,066.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,765 shares of company stock worth $6,016,700. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quent Capital LLC lifted its position in Natera by 3.2% during the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock worth $293,000 after buying an additional 99 shares in the last quarter. GAMMA Investing LLC lifted its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. Moss Adams Wealth Advisors LLC lifted its position in Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after purchasing an additional 135 shares during the period. Quarry LP lifted its position in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. Finally, Itau Unibanco Holding S.A. acquired a new position in Natera during the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.